Be a part of us in returning to NYC on June fifth to collaborate with government leaders in exploring complete strategies for auditing AI fashions concerning bias, efficiency, and moral compliance throughout various organizations. Discover out how one can attend right here.
Atropos Health, a healthcare know-how firm targeted on producing customized real-world proof, introduced as we speak that it has raised $33 million in a Series B funding round. The spherical included strategic investments from healthcare giants McKesson, Merck, and Cencora Ventures, signaling robust business curiosity in Atropos’ mission to deliver automated, high-quality proof to affected person care choices.
The Silicon Valley-based startup plans to make use of the brand new capital to broaden its operations and double down on key initiatives equivalent to launching in life sciences, increasing channel partnerships in value-based care and oncology, and rising its proof community of knowledge companions.
“We’re on a mission to deliver customized proof for care to everyone on this planet. So it’s one other step in that journey,” stated Atropos Well being CEO and co-founder, Brigham Hyde, PhD, in an interview with VentureBeat. “Particularly, we’ll be utilizing this to double down behind our strategic initiatives, which embrace persevering with our launch in life sciences and constructing on the nice traction we have now there, additionally doubling down behind channel companions, notably in value-based care and specialty care oncology.”
Shaping the way forward for healthcare supply with AI-powered medical proof era
Atropos’ core know-how, Geneva OS, makes use of AI and automation to quickly generate clinical-grade proof from real-world knowledge. Developed over almost a decade of analysis at Stanford, Geneva OS powers functions like Atropos’ generative AI assistant ChatRWD. The platform allows clinicians, researchers, and different healthcare stakeholders to shortly entry dependable medical proof customized to particular affected person populations — one thing the corporate says is missing in healthcare as we speak.
VB Occasion
The AI Influence Tour: The AI Audit
Be a part of us as we return to NYC on June fifth to have interaction with prime government leaders, delving into methods for auditing AI fashions to make sure equity, optimum efficiency, and moral compliance throughout various organizations. Safe your attendance for this unique invite-only occasion.
Request an invitation
“We discuss an idea known as the proof hole,” defined Hyde. “The stat that we have now is that solely about 14% of each day medical choices have any prime quality proof behind them. That’s type of surprising should you’re not in our fields. However the causes for it are recognized — publications within the literature are pushed by medical trials, we don’t run sufficient trials… What if we are able to use prime quality knowledge, analyzed accurately and precisely, to fill that proof hole?”
Closing the proof hole: Personalised insights for higher affected person outcomes
Closing this “proof hole” is central to Atropos’ mission. The corporate believes offering clinicians with quick access to customized proof based mostly on sufferers much like the one in entrance of them will result in higher outcomes. Hyde gave the instance of a doctor treating a coronary heart failure affected person:
“Now we have various affected person populations, they usually have comorbidities and completely different histories,” he stated. “What you actually need is evident proof for these subpopulations — proof that may not but exist in literature or medical trials… Let’s not deal with each coronary heart failure affected person the identical. Let’s discover the proof for sure subgroups that generate higher outcomes and management prices for these sufferers.”
Accelerating pharmaceutical R&D with real-world proof automation
Purposes of Atropos’ know-how prolong past point-of-care medical choice making as properly. The corporate has partnered with pharmaceutical giants like Janssen to speed up drug growth by producing proof to tell medical trial design, affected person recruitment, and extra. Hyde prompt the platform might even be used to simulate medical trials.
“What if we have now the power to get nice proof and perception earlier to speed up your trial design and growth,” Hyde instructed VentureBeat. “What if we are able to recruit extra successfully as a result of we have now that data, and extra trials are profitable? What if we might even simulate medical trials and know beforehand which of them possible succeed or not? All that is about decreasing cycle time in R&D and de-risking medical trials.”
Atropos’ Collection B comes at a time of accelerating curiosity in making use of generative AI to specialised domains like healthcare. However Hyde believes constructing belief by way of methodological rigor and transparency will probably be key to success.
“Whereas there’s been a variety of pleasure round LLMs, frankly, most of it issues us as a result of we’re fearful about hallucination charges,” he stated. “Geneva ensures that there’s no hallucinations, it’s medical grade high quality, it’s extremely clear — a decade of publications on the way it’s performed — and customers can belief what’s popping out of it.”
With recent capital and a star-studded roster of strategic backers, Atropos is well-positioned to deliver its imaginative and prescient of customized, automated medical proof to healthcare globally. However Hyde emphasised that that is just the start:
“I believe proof is the forex of worth in healthcare… What if I might give [doctors] extra proof, and extra customized, in order that they make a greater choice?” Hyde posited. “Essentially, we’re attempting to maneuver the world to some extent the place all sufferers and all suppliers have entry to high quality, customized proof for his or her choice making.”
